Quicker Reviews, Designated Funding Is Speeding COVID-19 Research Efforts at UF Health (UF Health Newsroom)

Quicker Reviews, Designated Funding Is Speeding COVID-19 Research Efforts at UF Health

University of Florida Health researcher Mark Brantly, M.D., and his team are working to evaluate a drug treatment for the novel coronavirus that might block the deadly inflammatory response caused by the disease that curtails the lungs’ ability to function.

In the absence of any known therapies for COVID-19, Brantly wanted to open a clinical trial on severely ill patients with respiratory distress to see if the treatment works.

First, though, he needed approval from UF Health’s Institutional Review Board. This committee of 21 physicians, nurses, pharmacists, researchers, and community members oversees all clinical trial protocols. This ensures all federal, state, and local rules and guidelines meant to protect patients’ rights and safety are followed.

Learn more about Quicker Reviews, Designated Funding Is Speeding COVID-19 Research Efforts at UF Health.
X